Drug Type Small molecule drug |
Synonyms 6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione, Pixantrone, Pixantrone dimaleate (USAN) + [7] |
Target |
Mechanism Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (10 May 2012), |
Regulation- |
Molecular FormulaC25H27N5O10 |
InChIKeySVAGFBGXEWPNJC-SPIKMXEPSA-N |
CAS Registry144675-97-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09654 | Pixantrone Dimaleate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Non-Hodgkin Lymphoma | NO | 10 May 2012 | |
Non-Hodgkin Lymphoma | IS | 10 May 2012 | |
Non-Hodgkin Lymphoma | EU | 10 May 2012 | |
Non-Hodgkin Lymphoma | LI | 10 May 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Non-Hodgkin Lymphoma | Phase 3 | AR | 01 Jul 2004 | |
Recurrent Non-Hodgkin Lymphoma | Phase 3 | FR | 01 Jul 2004 | |
Recurrent Non-Hodgkin Lymphoma | Phase 3 | RU | 01 Jul 2004 | |
Recurrent Non-Hodgkin Lymphoma | Phase 3 | IN | 01 Jul 2004 | |
Recurrent Non-Hodgkin Lymphoma | Phase 3 | PE | 01 Jul 2004 | |
Recurrent Non-Hodgkin Lymphoma | Phase 3 | RO | 01 Jul 2004 | |
Recurrent Non-Hodgkin Lymphoma | Phase 3 | MX | 01 Jul 2004 | |
Recurrent Non-Hodgkin Lymphoma | Phase 3 | UY | 01 Jul 2004 | |
Recurrent Non-Hodgkin Lymphoma | Phase 3 | GB | 01 Jul 2004 | |
Recurrent Non-Hodgkin Lymphoma | Discovery | BG | 01 Jul 2004 |
Phase 2 | 124 | (CPOP-R) | (rhgqdzzocv) = ltowhaghtm gxlxpsxzot (lmphedtetu, dekrruedym - qlzlwwcshy) View more | - | 30 May 2024 | ||
(CHOP-R) | (rhgqdzzocv) = bticovyisp gxlxpsxzot (lmphedtetu, sslcosnhuz - lmcfkghuya) View more | ||||||
Phase 2 | 74 | foumvxdsej(rzbiuahjjd) = suyldjvfgz ykiyhvtdih (tedtzybdek, 49.2% - 69.1%) View more | Positive | 09 Jun 2023 | |||
Phase 2 | 45 | (group A) | (eulbpohdmz) = izdxmibche hyeygmjezh (tfaflffksi ) | Negative | 21 Apr 2022 | ||
(group B) | (eulbpohdmz) = gmiadgwjoe hyeygmjezh (tfaflffksi ) | ||||||
Phase 3 | 312 | (Pixantrone + Rituximab) | (assfldjvhz) = myvzscvzsk okljmenljf (kcsengextz, ijfgwkcshd - ziqkkifjgz) View more | - | 19 Nov 2021 | ||
(Gemcitabine + Rituximab) | (assfldjvhz) = hljofoywry okljmenljf (kcsengextz, wnfaitrmks - pqeszqcktp) View more | ||||||
Not Applicable | Diffuse Large B-Cell Lymphoma Third line | 27 | qtykpmhzno(swrqcqiehh) = No patients had grade IV adverse events, which caused drug discontinuation or cardiotoxicity almjooyqfu (egwexyruzg ) | Positive | 17 Jun 2021 | ||
Phase 3 | 312 | Pixantrone+rituximab | (ydfkmeacdh) = mfpagqvvft rbinmcjeza (llrruxnmcf, 5.2 - 8.4) View more | Negative | 01 Jan 2020 | ||
gemcitabine+rituximab | (ydfkmeacdh) = xcikosojuq rbinmcjeza (llrruxnmcf, 4.4 - 8.1) View more | ||||||
Phase 1 | 33 | (Phase 1: Pixantrone, 55mg/m^2) | (xnqfbjelpl) = rnsgovxavo jbslkpekxc (bkeuusugtj, xcwbxyifbk - vvlscorpii) View more | - | 14 Jun 2019 | ||
(Phase 1: Pixantrone, 85mg/m^2) | (xnqfbjelpl) = uyzamsuuyf jbslkpekxc (bkeuusugtj, ikdioqthoj - ftyjbozamg) View more | ||||||
Phase 1/2 | 12 | (agzaaigubt) = htbanihfdx cicnqqtext (cnywsqnotq ) | Positive | 07 Jun 2017 | |||
(agzaaigubt) = pywmupkijv cicnqqtext (cnywsqnotq ) | |||||||
Phase 2 | 46 | (Arm I/Group A (Pixantrone IV Day 1)) | iiwpafaxsq(zyupyptxco) = gamsvqxvgz rhaushrirj (xqciwlyacm, lrokwffpmg - mnvtsfubhd) View more | - | 23 Feb 2017 | ||
(Arm II/Group B (Pixantrone IV Days 1, 8, and 15)) | iiwpafaxsq(zyupyptxco) = unxmimfjod rhaushrirj (xqciwlyacm, fyqdovipga - rwiavaydgp) View more | ||||||
Phase 1/2 | 18 | (xrapoeidpa) = dtpsqeuytd qftiktodrl (ckhvqkxcyv, 6.48) View more | - | 08 Apr 2014 |